Mayo Clinic Laboratories on Monday became the second commercial laboratory in the U.S. to begin monkeypox testing as part of an effort to increase testing capacity and access.
“The ability of commercial laboratories to test for monkeypox is an important pillar in our comprehensive strategy to combat this disease”
“This will not only increase testing capacity but also make it more convenient for providers and patients to access tests by using existing provider-to-laboratory networks.”
The Mayo Clinic said testing will be performed in its Department of Laboratory Medicine and Pathology in Rochester, Minnesota, “which is experienced in testing for rare infectious diseases.”
Patients can access testing through providers who use Mayo Clinic Laboratories as their reference laboratory.
The CDC expects additional laboratories named by HHS — Aegis Science, Quest Diagnostics and Sonic Healthcare — to begin testing later this summer as the monkeypox outbreak continues.
In addition to increased testing, the CDC has issued travel alerts and expanded access to vaccines in response to the outbreak.
WHO has so far declined to declare the outbreak a public health emergency of international concern, although an emergency committee plans to meet again on July 18 or sooner if to discuss the situation.